12 results
10-Q
2019 Q3
GRTX
Galera Therapeutics Inc
10 Dec 19
Quarterly report
7:31am
; and
our reputation may suffer.
Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular … candidates that we may develop;
injury to our reputation and significant negative media attention;
regulatory investigations that could require costly
10-K
2019 FY
GRTX
Galera Therapeutics Inc
10 Mar 20
Annual report
7:36am
to patients;
the product may become less competitive; and
our reputation may suffer.
Any of the foregoing events could prevent us from achieving … develop;
injury to our reputation and significant negative media attention;
regulatory investigations that could require costly recalls or product
DRS/A
xzxeahun4aq5ii04
9 Aug 19
Draft registration statement (amended)
12:00am
DRS/A
fqrruhrnzd3x5i vy28s
23 Apr 19
Draft registration statement (amended)
12:00am
DRS
ppz ej9qaqju
15 Mar 19
Draft registration statement
12:00am
S-1/A
9jy0s5 w6x5nhw
28 Oct 19
IPO registration (amended)
7:16am
DRS/A
944bn
12 Sep 19
Draft registration statement (amended)
12:00am
S-1
ntws2b6
11 Oct 19
IPO registration
5:27pm
424B4
kjuf8
8 Nov 19
Prospectus supplement with pricing info
4:41pm
- Prev
- 1
- Next